Home Cart Sign in  
Chemical Structure| 1903768-17-1 Chemical Structure| 1903768-17-1

Structure of Danicopan
CAS No.: 1903768-17-1

Chemical Structure| 1903768-17-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Danicopan is selective and orally active small-molecule factor D inhibitor, shows high binding affinity to human Factor D with Kd value of 0.54 nM. It has potential to block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).

Synonyms: ACH-4471; ACH-CFDIS; ALXN 2040

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Danicopan

CAS No. :1903768-17-1
Formula : C26H23BrFN7O3
M.W : 580.41
SMILES Code : O=C([C@H]1N(C(CN2N=C(C(C)=O)C3=C2C=CC(C4=CN=C(C)N=C4)=C3)=O)C[C@H](F)C1)NC5=NC(Br)=CC=C5
Synonyms :
ACH-4471; ACH-CFDIS; ALXN 2040
MDL No. :MFCD01018179
InChI Key :PIBARDGJJAGJAJ-NQIIRXRSSA-N
Pubchem ID :118323590

Safety of Danicopan

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT06449001 Paroxysmal Nocturnal Hemoglobi... More >>nuria|PNH|Extravascular Hemolysis Less << PHASE3 NOT_YET_RECRUITING 2028-01-12 -
NCT03555539 Hepatic Impairment PHASE1 COMPLETED 2018-09-21 Clinical Trial Site, Miami, Fl... More >>orida, 33136, United States|Clinical Trial Site, Orlando, Florida, 32809, United States Less <<
NCT03053102 Paroxysmal Nocturnal Hemoglobi... More >>nuria (PNH) Less << PHASE2 COMPLETED 2018-11-14 Clinical Trial Site, Florence,... More >> Italy|Clinical Trial Site, Naples, Italy|Clinical Trial Site, Seoul, Korea, Republic of|Clinical Trial Site, Auckland, New Zealand|Clinical Trial Site, London, United Kingdom Less <<
NCT04935294 Healthy|Renal Dysfunction PHASE1 COMPLETED 2018-05-29 Clinical Trial Site, Miami, Fl... More >>orida, 33014, United States|Clinical Trial Site, Orlando, Florida, 32809, United States|Clinical Trial Site, Minneapolis, Minnesota, 55404, United States|Clinical Trial Site, Saint Paul, Minnesota, 55114, United States Less <<
NCT04451434 Healthy PHASE1 COMPLETED 2020-09-28 Clinical Study Site, Brisbane,... More >> Australia Less <<
NCT03124368 C3 Glomerulonephritis|Dense De... More >>posit Disease|C3 Glomerulopathy|Immune Complex Mediated Membranoproliferative Glomerulonephritis|Membranoproliferative Glomerulonephritis Types I, II, and III Less << PHASE2 COMPLETED 2019-01-09 Clinical Trial Site, Melbourne... More >>, Australia|Clinical Trial Site, Antwerpen, Belgium|Clinical Trial Site, Leiden, Netherlands Less <<
NCT05389449 Paroxysmal Nocturnal Hemoglobi... More >>nuria Less << PHASE3 ACTIVE_NOT_RECRUITING 2027-01-31 Research Site, Los Angeles, Ca... More >>lifornia, 90089, United States|Research Site, Chicago, Illinois, 60612, United States|Research Site, Baltimore, Maryland, 21231, United States|Research Site, Kansas City, Missouri, 64111, United States|Research Site, Long Island City, New York, 11101, United States|Research Site, Cleveland, Ohio, 44195, United States|Research Site, Dallas, Texas, 75390-9047, United States|Research Site, Porto Alegre, 90110-270, Brazil|Research Site, Rio de Janeiro, 20211-080, Brazil|Research Site, Toronto, Ontario, M5G 2C4, Canada|Research Site, Brno, 625 00, Czechia|Research Site, Lille, 59037, France|Research Site, Paris, 75010, France|Research Site, Pessac, 33604, France|Research Site, Pierre Benite Cedex, 69495, France|Research Site, Athens, 11527, Greece|Research Site, Thessaloniki, 57010, Greece|Research Site, Haifa, 31048, Israel|Research Site, Jerusalem, 91120, Israel|Research Site, Avellino, 83100, Italy|Research Site, Bassano del Grappa, 36061, Italy|Research Site, Firenze, 50134, Italy|Research Site, Milano, 20122, Italy|Research Site, Reggio Calabria, 89131, Italy|Research Site, Roma, 161, Italy|Research Site, Bunkyo-Ku, 113 8603, Japan|Research Site, Kyoto-shi, 605-0981, Japan|Research Site, Osaka-shi, 530-8480, Japan|Research Site, Shibuya-ku, 150-8935, Japan|Research Site, Tsukuba-shi, 305-8576, Japan|Research Site, Seoul, 03722, Korea, Republic of|Research Site, Seoul, 06591, Korea, Republic of|Research Site, Suwon, 16247, Korea, Republic of|Research Site, Kota Kinabalu, 88586, Malaysia|Research Site, Kuching, 93200, Malaysia|Research Site, Miri, 98000, Malaysia|Research Site, Gdańsk, 80-952, Poland|Research Site, Badalona, 8916, Spain|Research Site, Barcelona, 08036, Spain|Research Site, Majadahonda, 28222, Spain|Research Site, Sevilla, 41013, Spain|Research Site, Bangkok, 10330, Thailand|Research Site, Airdrie, ML6 0JS, United Kingdom|Research Site, Leeds, LS9 7TF, United Kingdom|Research Site, London, SE5 9RS, United Kingdom Less <<
NCT03459443 C3 Glomerulonephritis|C3 Glome... More >>rulopathy|Immune Complex Membranoproliferative Glomerulonephritis|IC-MPGN|Dense Deposit Disease Less << PHASE2 TERMINATED 2021-03-29 Clinical Study Site, Birmingha... More >>m, Alabama, 35294, United States|Clinical Study Site, Stanford, California, 94305, United States|Clinical Study Site, New Haven, Connecticut, 06511, United States|Clinical Study Site, Cincinnati, Ohio, 45221, United States|Clinical Study Site, Columbus, Ohio, 43210, United States|Clinical Study Site, Philadelphia, Pennsylvania, 19104, United States|Clinical Study Site, Sydney, New South Wales, Australia|Clinical Study Site, Brisbane, Queensland, Australia|Clinical Study Site, Melbourne, Victoria, Australia|Clinical Study Site, Antwerpen, Belgium|Clinical Study Site, Ranica, Italy|Clinical Study Site, Leiden, Netherlands|Clinical Study Site, Nijmegen, Netherlands Less <<
NCT05982938 Paroxysmal Nocturnal Hemoglobi... More >>nuria|PNH|Extravascular Hemolysis Less << AVAILABLE - -
NCT04551599 Healthy PHASE1 COMPLETED 2021-02-03 Clinical Trial Site, Tempe, Ar... More >>izona, 85283, United States Less <<
NCT03181633 Paroxysmal Nocturnal Hemoglobi... More >>nuria Less << PHASE2 COMPLETED 2022-01-04 Clinical Trial Site, Avellino,... More >> Italy|Clinical Trial Site, Naples, Italy|Clinical Trial Site, Seoul, Korea, Republic of|Clinical Trial Site, Auckland, New Zealand Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.72mL

0.34mL

0.17mL

8.61mL

1.72mL

0.86mL

17.23mL

3.45mL

1.72mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories